Acacia Research (ACTG - Snapshot Report) has consistently been a Zacks #4 Rank (Sell) or #5 Rank (Strong Sell) for most of the past two years. In that time, the stock has fallen from $30 to new 5-year lows this month under $9.60.

Acacia Research Corporation, through its subsidiaries, develops, acquires, and licenses patented technologies. It assists patent owners with the prosecution and development of their patent portfolios, protection of their patented inventions from unauthorized use, generation of licensing revenue from users of their patented technologies and enforcement against unauthorized users of their patented technologies.

The slide in ACTG shares really accelerated this year as analyst earnings estimates plummeted further. Here's what I wrote in March when I profiled this earnings evaporation...

"In just the past 60 days, the consensus EPS estimate for this year dropped from $0.62 to $0.50 while those for next year fell from $1.23 to $0.86, a 30% wipeout."

Today's update: 90 days later, those full-year EPS estimates have cascaded from $0.50 to $0.21 for 2015 and from $0.86 to $0.68 for 2016. The evaporation continues.

You can see the longer-term EPS decline in the Zacks proprietary Price & Consensus chart...

Until this earnings evaporation stops and reverses, it's probably best to keep this portfolio of patents out of yours.